



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2011

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

International Consortium for Blood Pressure Genome-Wide Associat ; et al ; Devuyst, O

Abstract: Blood pressure is a heritable trait influenced by several biological pathways and responsive to environmental stimuli. Over one billion people worldwide have hypertension (140 mm Hg systolic blood pressure or 90 mm Hg diastolic blood pressure). Even small increments in blood pressure are associated with an increased risk of cardiovascular events. This genome-wide association study of systolic and diastolic blood pressure, which used a multi-stage design in 200,000 individuals of European descent, identified sixteen novel loci: six of these loci contain genes previously known or suspected to regulate blood pressure (GUCY1A3-GUCY1B3, NPR3-C5orf23, ADM, FURIN-FES, GOSR2, GNAS-EDN3); the other ten provide new clues to blood pressure physiology. A genetic risk score based on 29 genome-wide significant variants was associated with hypertension, left ventricular wall thickness, stroke and coronary artery disease, but not kidney disease or kidney function. We also observed associations with blood pressure in East Asian, South Asian and African ancestry individuals. Our findings provide new insights into the genetics and biology of blood pressure, and suggest potential novel therapeutic pathways for cardiovascular disease prevention.

DOI: <https://doi.org/10.1038/nature10405>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-53219>

Journal Article

Accepted Version

Originally published at:

International Consortium for Blood Pressure Genome-Wide Associat; et al; Devuyst, O (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*, 478(7367):103-109.

DOI: <https://doi.org/10.1038/nature10405>

1

2

3

Genetic Variants in Novel Pathways Influence Blood Pressure

4

and Cardiovascular Disease Risk

5

6

The International Consortium for Blood Pressure Genome-Wide Association Studies

7

A full list of authors is provided at the end of the manuscript

8

Blood pressure (BP) is a heritable trait¹ influenced by multiple biological pathways and is responsive to environmental stimuli. Over one billion people worldwide have hypertension (BP ≥ 140 mm Hg systolic [SBP] or ≥ 90 mm Hg diastolic [DBP])². Even small increments in BP are associated with increased risk of cardiovascular events³. This genome-wide association study of SBP and DBP, which used a multi-stage design in 200,000 individuals of European descent, identified 16 novel loci: six of these loci contain genes previously known or suspected to regulate BP (*GUCY1A3-GUCY1B3*; *NPR3-C5orf23*; *ADM*; *FURIN-FES*; *GOSR2*; *GNAS-EDN3*); the other 10 provide new clues to BP physiology. A genetic risk score based on 29 genome-wide significant variants was associated with hypertension, left ventricular wall thickness, stroke, and coronary artery disease, but not kidney disease or kidney function. We also observed associations with BP in East Asian, South Asian, and African ancestry individuals. Our findings provide new insights into the genetics and biology of BP, and suggest novel potential therapeutic pathways for cardiovascular disease prevention.

Genetic approaches have advanced the understanding of biological pathways underlying inter-individual variation in BP. For example, studies of rare Mendelian BP disorders have identified multiple defects in renal sodium handling pathways⁴. More recently two genome-wide association studies (GWAS), each of >25,000 individuals of European-ancestry, identified 13 loci associated with SBP, DBP, and hypertension^{5,6}. We now report results of a new meta-analysis of GWAS data that includes staged follow-up genotyping to identify additional BP loci.

Primary analyses evaluated associations between 2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) and SBP and DBP in 69,395 individuals of European

ancestry from 29 studies (Supplementary Materials Sections 1-3, Supplementary Tables 1-2). Following GWAS meta-analysis, we conducted a three-stage validation experiment that made efficient use of available genotyping resources, to follow up top signals in up to 133,661 additional individuals of European descent (Supplementary Fig. 1 and Supplementary Materials Section 4). Twenty-nine independent SNPs at 28 loci were significantly associated with SBP, DBP, or both in the meta-analysis combining discovery and follow up data (Fig. 1, Table 1, Supplementary Figs 2-3, Supplementary Tables 3-5). All 29 SNPs attained association $P < 5 \times 10^{-9}$, an order of magnitude beyond the standard genome-wide significance level for a single stage experiment (Table 1).

Sixteen of these 29 associations were novel (Table 1). Two associations were near the *FURIN* and *GOSR2* genes; prior targeted analyses of variants in these genes suggested they may be BP loci^{7,8}. At the *CACNB2* locus we validated association for a previously reported⁶ SNP rs4373814 and detected a novel independent association for rs1813353 (pairwise $r^2 = 0.015$ in HapMap CEU). Of our 13 previously reported associations^{5,6}, only the association at *PLCD3* was not supported by the current results (Supplementary Table 4). Some of the associations are in or near genes involved in pathways known to influence BP (*NPR3*, *GUCY1A3-GUCY1B3*, *ADM*, *GNAS-EDN3*, *NPPA-NPPB*, and *CYP17A1*; Supplementary Fig. 4). Twenty-two of the 28 loci did not contain genes that were *a priori* strong biological candidates.

As expected from prior BP GWAS results, the effects of the novel variants on SBP and DBP were small (Fig. 1 and Table 1). For all variants, the observed directions of effects were concordant for SBP, DBP, and hypertension (Fig. 1, Table 1, Supplementary Fig. 3). Among the genes at the genome-wide significant loci, only *CYP17A1*, previously implicated in Mendelian congenital adrenal hyperplasia and hypertension, is known to harbour rare

variants that have large effects on BP⁹.

We performed several analyses to identify potential causal alleles and mechanisms. First, we looked up the 29 genome-wide significant index SNPs and their close proxies ($r^2 > 0.8$) among *cis*-acting expression SNP (eSNP) results from multiple tissues (Supplementary Materials Section 5). For 13/29 index SNPs, we found association between nearby eSNP variants and expression level of at least one gene transcript ($10^{-4} > p > 10^{-51}$, Supplementary Table 6). In 5 cases, the index BP SNP and the best eSNP from a genome-wide survey were identical, highlighting potential mediators of the SNP-BP associations.

Second, because changes in protein sequence are strong *a priori* candidates to be functional, we sought non-synonymous coding SNPs that were in high LD ($r^2 > 0.8$) with the 29 index SNPs. We identified such SNPs at 8 loci (Table 1, Supplementary Materials Section 6, Supplementary Table 7). In addition we performed analyses testing for differences in genetic effect according to body mass index (BMI) or sex, and analyses of copy number variants, pathway enrichment, and metabolomic data, but we did not find any statistically significant results (Supplementary Materials Sections 7-9, Supplementary Tables 8-10).

We evaluated whether the BP variants we identified in Europeans were associated with BP in individuals of East Asian (N=29,719), South Asian (N=23,977), and African (N=19,775) ancestries (Table 1, Supplementary Tables 11-13). We found significant associations in individuals of East Asian ancestry for SNPs at 9 loci and in individuals of South Asian ancestry for SNPs at 6 loci; some have been reported previously (Supplementary Tables 12 and 15). The lack of significant association for individual SNPs may reflect small sample sizes, differences in allele frequencies or LD patterns, imprecise imputation for some ancestries using existing reference samples, or a genuinely different underlying genetic architecture. Because of limited power to detect effects of individual

variants in the smaller non-European samples, we created genetic risk scores for SBP and DBP incorporating all 29 BP variants weighted according to effect sizes observed in the European samples. In each non-European ancestry group, risk scores were strongly associated with SBP ($P=1.1 \times 10^{-40}$ in East Asian, $P=2.9 \times 10^{-13}$ in South Asian, $P=9.8 \times 10^{-4}$ in African ancestry individuals) and DBP ($P=2.9 \times 10^{-48}$, $P=9.5 \times 10^{-15}$, and $P=5.3 \times 10^{-5}$, respectively; Supplementary Table 13).

We also created a genetic risk score to assess association of the variants in aggregate with hypertension and with clinical measures of hypertensive complications including left ventricular mass, left ventricular wall thickness, incident heart failure, incident and prevalent stroke, prevalent coronary artery disease (CAD), kidney disease, and measures of kidney function, using results from other GWAS consortia (Table 2, Supplementary Materials Sections 10-11, Supplementary Table 14). The risk score was weighted using the average of SBP and DBP effects for the 29 SNPs. In an independent sample of 23,294 women¹⁰, an increase of 1 standard deviation in the genetic risk score was associated with a 21% increase in the odds of hypertension (95% CI 19%-28%; Table 2, Supplementary Table 14). Among individuals in the top decile of the risk score, the prevalence of hypertension was 29% compared with 16% in the bottom decile (odds ratio 2.09, 95% CI 1.86-2.36). Similar results were observed in an independent hypertension case-control sample (Table 2). In our study, individuals in the top compared to bottom quintiles of genetic risk score differed by 4.6 mm Hg SBP and 3.0 mm Hg DBP, differences that approach population-averaged BP treatment effects for a single antihypertensive agent¹¹. Epidemiologic data have shown that differences in SBP and DBP of this magnitude, across the population range of BP, are associated with an increase in cardiovascular disease risk³. Consistent with this and in line with findings from randomized trials of BP-lowering

medication in hypertensive patients^{12,13}, the genetic risk score was positively associated with left ventricular wall thickness ($P=6.0\times 10^{-6}$), occurrence of stroke ($P=3.3\times 10^{-5}$) and CAD ($P=8.1\times 10^{-29}$). The same genetic risk score was not, however, significantly associated with chronic kidney disease or measures of kidney function, even though these renal outcomes were available in a similar sample size as for the other outcomes (Table 2). The absence of association with kidney phenotypes could be explained by a weaker causal relation of BP with kidney phenotypes than with CAD and stroke. This finding is consistent with the mismatch between observational data that show a positive association of BP with kidney disease, and clinical trial data that show inconsistent evidence of benefit of BP lowering on kidney disease prevention in patients with hypertension¹⁴. Thus, several lines of evidence converge to suggest that BP elevation may in part be a consequence rather than a cause of sub-clinical kidney disease.

Our discovery meta-analysis (Supplementary Fig. 2) suggests an excess of modestly significant ($10^{-5} < P < 10^{-2}$) associations likely arising from common BP variants of small effect. By dividing our principal GWAS dataset into non-overlapping discovery ($N\approx 56,000$) and validation ($N\approx 14,000$) subsets, we found robust evidence for the existence of such undetected common variants (Supplementary Fig. 5, Supplementary Materials Section 12). We estimate¹⁵ that there are 116 (95% CI 57-174) independent BP variants with effect sizes similar to those reported here, which collectively explain $\approx 2.2\%$ of the phenotypic variance for SBP and DBP, compared with 0.9% explained by the 29 associations discovered thus far (Supplementary Fig. 6, Supplementary Materials Section 13).

Most of the 28 BP loci harbour multiple genes (Supplementary Table 15, Supplementary Fig. 4), and although substantial research is required to identify the specific genes and variants responsible for these associations, several loci contain highly plausible

biological candidates. The *NPPA* and *NPPB* genes at the *MTHFR-NPPB* locus encode precursors for atrial- and B-type natriuretic peptides (ANP, BNP), and previous work has identified SNPs, modestly correlated with our index SNP at this locus, that are associated with plasma ANP, BNP, and BP¹⁶. We found the index SNP at this locus was associated with opposite effects on BP and on ANP/BNP levels, consistent with a model in which the variants act through increased ANP/BNP production to lower BP¹⁶ (Supplementary Materials Section 14).

Two other loci identified in the current study harbour genes involved in natriuretic peptide and related nitric oxide signalling pathways,^{17,18} both of which act to regulate cyclic guanosine monophosphate (cGMP). The first locus contains *NPR3*, which encodes the natriuretic peptide clearance receptor (NPR-C). *NPR3* knockout mice exhibit reduced clearance of circulating natriuretic peptides and lower BP¹⁹. The second locus includes *GUCY1A3* and *GUCY1B3*, encoding the alpha and beta subunits of soluble guanylate cyclase (sGC); knockout of either gene in murine models results in hypertension²⁰.

Another locus contains *ADM*, encoding adrenomedullin, which has natriuretic, vasodilatory, and BP-lowering properties²¹. At the *GNAS-EDN3* locus, *ZNF831* is closest to the index SNP, but *GNAS* and *EDN3* are two nearby compelling biological candidates (Supplementary Fig. 4, Supplementary Table 15).

We identified two loci with plausible connections to BP via genes implicated in renal physiology or kidney disease. At the first locus, *SLC4A7* is an electro-neutral sodium bicarbonate co-transporter expressed in the nephron and in vascular smooth muscle²². At the second locus, *PLCE1* (phospholipase-C-epsilon-1 isoform) is important for normal podocyte development in the glomerulus; sequence variation in *PLCE1* has been implicated in familial nephrotic syndromes and end-stage kidney disease²³.

Missense variants in two genes involved in metal ion transport were associated with BP in our study. The first encodes a His/Asp change at amino acid 63 (*H63D*) in *HFE* and is a low penetrance allele for hereditary hemochromatosis²⁴. The second is an Ala/Thr polymorphism located in exon 7 of *SLC39A8*, which encodes a zinc transporter that also transports cadmium and manganese²⁵. The same allele of *SLC39A8* associated with BP in our study has recently been associated with high-density lipoprotein (HDL) cholesterol levels²⁶ and BMI²⁷ (Supplementary Table 15).

In conclusion, we have shown that 29 independent genetic variants influence BP in people of European ancestry. The variants reside in 28 loci, 16 of which were novel, and we confirmed association of several of them in individuals of non-European ancestry. A risk score derived from the 29 variants was significantly associated with BP-related organ damage and clinical cardiovascular disease, but not kidney disease. These loci improve our understanding of the genetic architecture of BP, provide new biological insights into BP control and may identify novel targets for the treatment of hypertension and the prevention of cardiovascular disease.

Methods summary

Supplementary Materials provide complete methods and include the following sections: study recruitment and phenotyping, adjustment for antihypertensive medications, genotyping, data quality control, genotype imputation, within-cohort association analyses, meta-analyses of discovery and validation stages, stratified analyses by sex and BMI, identification of eSNPs and nsSNPs, metabolomic and lipidomic analyses, CNV analyses, pathway analyses, analyses for non-European ancestries, association of a risk score with hypertension and cardiovascular disease, estimation of numbers of undiscovered variants, measurement of natriuretic peptides, and brief literature reviews and GWAS database lookups of all validated BP loci.

Note added in proof: Since this manuscript was submitted, Kato et al published a BP GWAS in East Asians that identified a SNP highly correlated to the SNP we report at the *NPR3-c5orf23* locus²⁸.

References

- 1 Levy, D. *et al.* Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. *Hypertension* **36**. 477-483, (2000).
- 2 Kearney, P. M. *et al.* Global burden of hypertension: analysis of worldwide data. *Lancet* **365**. 217-223, (2005).
- 3 Lewington, S., Clarke, R., Qizilbash, N., Peto, R. & Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* **360**. 1903-1913, (2002).
- 4 Lifton, R. P., Gharavi, A. G. & Geller, D. S. Molecular mechanisms of human hypertension. *Cell* **104**. 545-556, (2001).
- 5 Newton-Cheh, C. *et al.* Genome-wide association study identifies eight loci associated with blood pressure. *Nat Genet* **41**. 666-676, (2009).
- 6 Levy, D. *et al.* Genome-wide association study of blood pressure and hypertension. *Nat Genet* **41**. 677-687, (2009).
- 7 Meyer, T. E. *et al.* GOSR2 Lys67Arg is associated with hypertension in whites. *Am J Hypertens* **22**. 163-168, (2009).
- 8 Li, N. *et al.* Associations between genetic variations in the *FURIN* gene and hypertension. *BMC Med Genet* **11**. 124, (2010).
- 9 Mussig, K. *et al.* 17 α -hydroxylase/17,20-lyase deficiency caused by a novel homozygous mutation (Y27Stop) in the cytochrome CYP17 gene. *J Clin Endocrinol Metab* **90**. 4362-4365, (2005).
- 10 Ridker, P. M. *et al.* Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. *Clin Chem* **54**. 249-255, (2008).
- 11 Burt, V. L. *et al.* Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. *Hypertension* **26**. 60-69, (1995).
- 12 Turnbull, F. *et al.* Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ* **336**. 1121-1123, (2008).
- 13 Law, M. R., Morris, J. K. & Wald, N. J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* **338**. b1665, (2009).
- 14 Lewis, J. B. Blood pressure control in chronic kidney disease: is less really more? *J Am Soc Nephrol* **21**. 1086-1092, (2010).
- 15 Park, J. H. *et al.* Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. *Nat Genet* **42**. 570-575, (2010).
- 16 Newton-Cheh, C. *et al.* Association of common variants in *NPPA* and *NPPB* with circulating natriuretic peptides and blood pressure. *Nat Genet* **41**. 348-353, (2009).
- 17 Schenk, D. B. *et al.* Purification and subunit composition of atrial natriuretic peptide receptor. *Proc Natl Acad Sci U S A* **84**. 1521-1525, (1987).
- 18 Schmidt, H. H. & Walter, U. NO at work. *Cell* **78**. 919-925, (1994).
- 19 Matsukawa, N. *et al.* The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. *Proc Natl Acad Sci U S A* **96**. 7403-7408, (1999).

- 20 Friebe, A., Mergia, E., Dangel, O., Lange, A. & Koesling, D. Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. *Proc Natl Acad Sci U S A* **104**. 7699-7704, (2007).
- 21 Ishimitsu, T., Ono, H., Minami, J. & Matsuoka, H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. *Pharmacol Ther* **111**. 909-927, (2006).
- 22 Pushkin, A. *et al.* Cloning, tissue distribution, genomic organization, and functional characterization of NBC3, a new member of the sodium bicarbonate cotransporter family. *J Biol Chem* **274**. 16569-16575, (1999).
- 23 Hinkes, B. *et al.* Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. *Nat Genet* **38**. 1397-1405, (2006).
- 24 Feder, J. N. *et al.* A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* **13**. 399-408, (1996).
- 25 He, L., Wang, B., Hay, E. B. & Nebert, D. W. Discovery of ZIP transporters that participate in cadmium damage to testis and kidney. *Toxicology and applied pharmacology* **238**. 250-257, (2009).
- 26 Teslovich, T. M. *et al.* Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* **466**. 707-713, (2010).
- 27 Speliotes, E. K. *et al.* Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet* **42**. 937-948, (2010).
- 28 Kato, N. *et al.* Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. *Nat Genet* **43**. 531-538, (2011).

Figure legends

Fig. 1. Genome-wide $-\log_{10} P$ -value plots and effects for significant loci.

Genome-wide $-\log_{10} P$ -value plots are shown for systolic (SBP: panel a) and diastolic (DBP: panel b). SNPs within loci reaching genome-wide significance are labeled in red for SBP and blue for DBP ($\pm 2.5\text{Mb}$ of lowest P -value) and lowest P -values in the initial genome-wide analysis as well as the results of analysis including validation data are labeled separately. The lowest P -values in the initial GWAS are denoted as an X. The range of different sample sizes in the final meta-analysis including the validation data are indicated as: circle (96-140k), triangle (>140 -180k), and diamond (>180 -220k). SNPs near unconfirmed loci are in black. The horizontal dotted line is $P=2.5 \times 10^{-8}$. Panel c shows the effect size estimates and 95% confidence bars per BP-increasing allele of the 29 significant variants for SBP (red) and DBP (blue). Effect sizes are expressed in mmHg/allele. GUCY = *GUCY1A3-GUCY1B3*.

Table legends

Table 1. Summary association results for 29 BP SNPs.

Summary association statistics, based on combined discovery and follow-up data, for 29 independent SNPs in individuals of European ancestry are shown. New genome-wide significant findings (17 SNPs) are presented in the top half of the table, data on 12 previously published signals are presented in the lower half. Y indicates the BP index SNP is a nsSNP, Y(p) indicates a proxy SNP is a nsSNP. Y(+): indicates BP index SNP is the strongest known eSNP for a transcript; Y(-): indicates BP index SNP is an eSNP but not strongest known eSNP for any transcript. Y(r): indicates BP index SNP is strongest known eSNP in a regional SNP-RTPCR experiment. Y(p): indicates a proxy SNP ($r^2 > 0.8$) to BP SNP is an eSNP

but not the strongest known eSNP. Observed effect directions in East Asian (EA), South Asian (SA), and African (A) ancestry individuals are coded + or - if concordant or discordant with directions in European ancestry results; * denotes significance controlling the FDR at 5% over 58 tests per ancestry (Supplementary Tables 5 and 12). Effect size estimates (beta) correspond to mm Hg per coded allele for SBP and DBP and ln(odds) per coded allele for HTN. CA = coded allele; NCA = non-coded allele; CAF = coded allele frequency; ? denotes missing data. Genomic positions use NCBI Build 36 coordinates.

Table 2. Genetic risk score and cardiovascular outcome association results.

Association of genetic risk score (using all 29 SNPs at 28 loci, parameterised using the average of SBP and DBP effects $[(SBP \text{ effect} + DBP \text{ effect})/2]$ from the discovery analysis), tested in results from other GWAS consortia.

(a) Units are the unit of phenotypic measurement, either per SD of genetic risk score, or as a difference between top/bottom quintiles or deciles. (b) Units are ln(odds) per SD of genetic risk score, or odds ratio between top/bottom quintiles or deciles. (c) Units are ln(hazard) per SD of genetic risk score, or hazard ratio between top/bottom quintiles or deciles. (d) Units are ln(phenotype) per SD of genetic risk score, or phenotypic ratio between top/bottom quintiles or deciles.

Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk

Table 1

Locus	Index SNP	Chr	Position	CA/NCA	CAF	nsSNP	eSNP	SBP			DBP			HTN	
								Beta	P-value	Effect in EA/SA/A	Beta	P-value	Effect in EA/SA/A	Beta	P-value
<i>MOV10</i>	rs2932538	1	113,018,066	G/A	0.75	Y(p)	Y(p)	0.388	1.2×10^{-9}	+ / + / -	0.24	9.9×10^{-10}	+ / + * / -	0.049	2.9×10^{-7}
<i>SLC4A7</i>	rs13082711	3	27,512,913	T/C	0.78	Y(p)	Y(p)	-0.315	1.5×10^{-6}	- / - / +	-0.238	3.8×10^{-9}	- / - / +	-0.035	3.6×10^{-4}
<i>MECOM</i>	rs419076	3	170,583,580	T/C	0.47	-	-	0.409	1.8×10^{-13}	+ / + / +	0.241	2.1×10^{-12}	+ / + / -	0.031	3.1×10^{-4}
<i>SLC39A8</i>	rs13107325	4	103,407,732	T/C	0.05	Y	Y(+)	-0.981	3.3×10^{-14}	? / + / +	-0.684	2.3×10^{-17}	? / + / +	-0.105	4.9×10^{-7}
<i>GUCY1A3-GUCY1B3</i>	rs13139571	4	156,864,963	C/A	0.76	-	-	0.321	1.2×10^{-6}	+ / - / +	0.26	2.2×10^{-10}	+ / - / +	0.042	2.5×10^{-5}
<i>NPR3-CSorf23</i>	rs11737771	5	32,850,785	G/A	0.6	-	-	0.504	1.8×10^{-16}	+ * / + / +	0.261	9.1×10^{-12}	+ * / + / -	0.062	3.2×10^{-10}
<i>EBF1</i>	rs11953630	5	157,777,980	T/C	0.37	-	-	-0.412	3.0×10^{-11}	+ / + / +	-0.281	3.8×10^{-13}	+ / + / +	-0.052	1.7×10^{-7}
<i>HFE</i>	rs1799945	6	26,199,158	G/C	0.14	Y	-	0.627	7.7×10^{-12}	+ / + / -	0.457	1.5×10^{-15}	+ / + / -	0.095	1.8×10^{-10}
<i>BAT2-BAT5</i>	rs805303	6	31,724,345	G/A	0.61	Y(p)	Y(+)	0.376	1.5×10^{-11}	- / - / ?	0.228	3.0×10^{-11}	- / - / +	0.054	1.1×10^{-10}
<i>CACNB2(5')</i>	rs4373814	10	18,459,978	G/C	0.55	-	-	-0.373	4.8×10^{-11}	+ / + / -	-0.218	4.4×10^{-10}	- / + / -	-0.046	8.5×10^{-8}
<i>PLCE1</i>	rs932764	10	95,885,930	G/A	0.44	-	-	0.484	7.1×10^{-16}	+ / + / -	0.185	8.1×10^{-7}	+ / + / -	0.055	9.4×10^{-9}
<i>ADM</i>	rs7129220	11	10,307,114	G/A	0.89	-	-	-0.619	3.0×10^{-12}	? / - / +	-0.299	6.4×10^{-8}	? / - / +	-0.044	1.1×10^{-3}
<i>FLJ32810-TMEM133</i>	rs633185	11	100,098,748	G/C	0.28	-	-	-0.565	1.2×10^{-17}	+ * / + / +	-0.328	2.0×10^{-15}	+ * / + / -	-0.07	5.4×10^{-11}
<i>FURIN-FES</i>	rs2521501	15	89,238,392	T/A	0.31	-	Y(-)	0.65	5.2×10^{-19}	+ * / + / +	0.359	1.9×10^{-15}	+ * / + / +	0.059	7.0×10^{-7}
<i>GOSR2</i>	rs17608766	17	42,368,270	T/C	0.86	-	Y(+)	-0.556	1.1×10^{-10}	+ / - / +	-0.129	0.017	+ / - / +	-0.025	0.08
<i>JAG1</i>	rs1327235	20	10,917,030	G/A	0.46	-	-	0.34	1.9×10^{-8}	+ * / + / +	0.302	1.4×10^{-15}	+ * / + * / +	0.034	4.6×10^{-4}
<i>GNAS-EDN3</i>	rs6015450	20	57,184,512	G/A	0.12	Y(p)	-	0.896	3.9×10^{-23}	? / + / +	0.557	5.6×10^{-23}	? / + * / +	0.11	4.2×10^{-14}
<i>MTHFR-NPPB</i>	rs17367504	1	11,785,365	G/A	0.15	-	Y(-/r)	-0.903	8.7×10^{-22}	+ / + / +	-0.547	3.5×10^{-19}	+ / + / +	-0.103	2.3×10^{-10}
<i>ULK4</i>	rs3774372	3	41,852,418	T/C	0.83	Y	Y(r/p)	-0.067	0.39	- / - / +	-0.367	9.0×10^{-14}	+ / + / +	-0.017	0.18
<i>FGF5</i>	rs1458038	4	81,383,747	T/C	0.29	-	-	0.706	1.5×10^{-23}	+ * / + / +	0.457	8.5×10^{-25}	+ * / + * / +	0.072	1.9×10^{-7}
<i>CACNB2(3')</i>	rs1813353	10	18,747,454	T/C	0.68	-	-	0.569	2.6×10^{-12}	+ / + / +	0.415	2.3×10^{-15}	+ / + / +	0.078	6.2×10^{-10}
<i>C10orf107</i>	rs4590817	10	63,137,559	G/C	0.84	-	Y(r)	0.646	4.0×10^{-12}	- / + / -	0.419	1.3×10^{-12}	- / - / -	0.096	9.8×10^{-9}
<i>CYP17A1-NT5C2</i>	rs11191548	10	104,836,168	T/C	0.91	-	Y(-)	1.095	6.9×10^{-26}	+ * / + * / +	0.464	9.4×10^{-13}	+ * / + * / +	0.097	1.4×10^{-5}
<i>PLEKHA7</i>	rs381815	11	16,858,844	T/C	0.26	-	-	0.575	5.3×10^{-11}	+ * / + / +	0.348	5.3×10^{-10}	+ * / - / +	0.062	3.4×10^{-6}
<i>ATP2B1</i>	rs17249754	12	88,584,717	G/A	0.84	-	-	0.928	1.8×10^{-18}	+ * / + * / -	0.522	1.2×10^{-14}	+ * / + * / -	0.126	1.1×10^{-14}
<i>SH2B3</i>	rs3184504	12	110,368,991	T/C	0.47	Y	Y(+)	0.598	3.8×10^{-18}	- / - / +	0.448	3.6×10^{-25}	- / - / +	0.056	2.6×10^{-6}
<i>TBX5-TBX3</i>	rs10850411	12	113,872,179	T/C	0.7	-	-	0.354	5.4×10^{-8}	- / + / -	0.253	5.4×10^{-10}	- / - / -	0.045	5.2×10^{-6}
<i>CYP1A1-ULK3</i>	rs1378942	15	72,864,420	C/A	0.35	-	Y(+)	0.613	5.7×10^{-23}	+ * / + / +	0.416	2.7×10^{-26}	+ * / + / -	0.073	1.0×10^{-8}
<i>ZNF652</i>	rs12940887	17	44,757,806	T/C	0.38	-	Y(-)	0.362	1.8×10^{-10}	+ / - / +	0.27	2.3×10^{-14}	+ / - / +	0.046	1.2×10^{-7}

Table 2

Phenotype	Source	Effect	SE		P-value	# SNPs	Contrast top vs. bottom			N case/control or total
		(per SD of genetic risk score)					quintiles	deciles		
Blood pressure phenotypes										
SBP [mmHg]	WGHS	1.645	0.098	(a)	6.5*10 ⁻⁶³	29	4.61	5.77	(a)	23,294
DBP [mmHg]	WGHS	1.057	0.067	(a)	8.4*10 ⁻⁵⁷	29	2.96	3.71	(a)	23,294
Prevalent hypertension	WGHS	0.211	0.018	(b)	3.1*10 ⁻³³	29	1.80	2.09	(b)	5,018/18,276
Prevalent hypertension	BRIGHT	0.287	0.031	(b)	7.7*10 ⁻²¹	29	2.23	2.74	(b)	2,406/1,990
Dichotomous endpoints										
Incident heart failure	CHARGE-HF	0.035	0.021	(c)	0.10	29	1.10	1.13	(c)	2,526/18,400
Incident stroke	NEURO-CHARGE	0.103	0.028	(c)	0.0002	28	1.34	1.44	(c)	1,544/18,058
Prevalent stroke	UK-US Stroke Collaborative Group(SCG)	0.075	0.037	(b)	0.05	29	1.23	1.30	(b)	1,473/ 1,482
Stroke (combined, incident and prevalent)	CHARGE & SCG	NA	NA	NA	3.3*10 ⁻⁵	NA	NA	NA	NA	3,017/19,540
Prevalent CAD	CARDIoGRAM	0.092	0.010	(b)	1.6*10 ⁻¹⁹	28	1.29	1.38	(b)	22,233/64,726
Prevalent CAD	C4D ProCARDIS	0.132	0.022	(b)	2.2*10 ⁻⁹	29	1.45	1.59	(b)	5,720/ 4,381
Prevalent CAD	C4D HPS	0.083	0.027	(b)	0.002	29	1.26	1.34	(b)	2,704/ 2,804
Prevalent CAD (combined)	CARDIoGRAM & C4D	0.100	0.009	(b)	8.1*10 ⁻²⁹	29	1.32	1.42	(b)	30,657/71,911
Prevalent chronic kidney disease	CKDGen	0.014	0.015	(b)	0.35	29	1.04	1.05	(b)	5,807/61,286
Prevalent microalbuminuria	CKDGen	0.008	0.019	(b)	0.68	29	1.02	1.03	(b)	3,698/27,882
Continuous measures of target organ damage										
Left ventricular mass [g]	EchoGen	0.822	0.317	(a)	0.01	29	2.30	2.89	(a)	12,612
Left ventricular wall thickness[cm]	EchoGen	0.009	0.002	(a)	6.0*10 ⁻⁶	29	0.03	0.03	(a)	12,612
Serum creatinine	KidneyGen	-0.001	0.001	(d)	0.24	29	1.00	1.00	(d)	23,812
eGFR (4 parameter MDRD equation)	CKDGen	-0.0001	0.0009	(d)	0.93	29	1.00	1.00	(d)	67,093
Urinary albumin/creatinine ratio	CKDGen	0.005	0.007	(d)	0.43	29	1.01	1.02	(d)	31,580

Authors

Georg B. Ehret^{1,2,3*}, Patricia B. Munroe^{4*#}, Kenneth M. Rice^{5*}, Murielle Bochud^{2*}, Andrew D. Johnson^{6,7*}, Daniel I. Chasman^{8,9*}, Albert V. Smith^{10,11*}, Martin D. Tobin¹², Germaine C. Verwoert^{13,14,15}, Shih-Jen Hwang^{6,16,7}, Vasyi Pihur¹, Peter Vollenweider¹⁷, Paul F. O'Reilly¹⁸, Najaf Amin¹³, Jennifer L Bragg-Gresham¹⁹, Alexander Teumer²⁰, Nicole L. Glazer²¹, Lenore Launer²², Jing Hua Zhao²³, Yurii Aulchenko¹³, Simon Heath²⁴, Siim Söber²⁵, Afshin Parsa²⁶, Jian'an Luan²³, Pankaj Arora²⁷, Abbas Dehghan^{13,14,15}, Feng Zhang²⁸, Gavin Lucas²⁹, Andrew A. Hicks³⁰, Anne U. Jackson³¹, John F Peden³², Toshiko Tanaka³³, Sarah H. Wild³⁴, Igor Rudan^{35,36}, Wilmar Igl³⁷, Yuri Milaneschi³³, Alex N. Parker³⁸, Cristiano Fava^{39,40}, John C. Chambers^{18,41}, Ervin R. Fox⁴², Meena Kumari⁴³, Min Jin Go⁴⁴, Pim van der Harst⁴⁵, Wen Hong Linda Kao⁴⁶, Marketa Sjögren³⁹, D. G. Vinay⁴⁷, Myriam Alexander⁴⁸, Yasuharu Tabara⁴⁹, Sue Shaw-Hawkins⁴, Peter H. Whincup⁵⁰, Yongmei Liu⁵¹, Gang Shi⁵², Johanna Kuusisto⁵³, Bamidele Tayo⁵⁴, Mark Seielstad^{55,56}, Xueling Sim⁵⁷, Khanh-Dung Hoang Nguyen¹, Terho Lehtimäki⁵⁸, Giuseppe Matullo^{59,60}, Ying Wu⁶¹, Tom R. Gaunt⁶², N. Charlotte Onland-Moret^{63,64}, Matthew N. Cooper⁶⁵, Carl G.P. Platou⁶⁶, Elin Org²⁵, Rebecca Hardy⁶⁷, Santosh Dahgam⁶⁸, Jutta Palmen⁶⁹, Veronique Vitart⁷⁰, Peter S. Braund^{71,72}, Tatiana Kuznetsova⁷³, Cuno S.P.M. Uitterwaal⁶³, Adebawale Adeyemo⁷⁴, Walter Palmas⁷⁵, Harry Campbell³⁵, Barbara Ludwig⁷⁶, Maciej Tomaszewski^{71,72}, Ioanna Tzoulaki^{77,78}, Nicholette D. Palmer⁷⁹, CARDIoGRAM consortium⁸⁰, CKDGen Consortium⁸⁰, KidneyGen Consortium⁸⁰, EchoGen consortium⁸⁰, CHARGE-HF consortium⁸⁰, Thor Aspelund^{10,11}, Melissa Garcia²², Yen-Pei C. Chang²⁶, Jeffrey R. O'Connell²⁶, Nanette I. Steinle²⁶, Diederick E. Grobbee⁶³, Dan E. Arking¹, Sharon L. Kardia⁸¹, Alanna C. Morrison⁸², Dena Hernandez⁸³, Samer Najjar^{84,85}, Wendy L. McArdle⁸⁶, David Hadley^{50,87}, Morris J. Brown⁸⁸, John M. Connell⁸⁹, Aroon D. Hingorani⁹⁰, Ian N.M. Day⁶², Debbie A. Lawlor⁶², John P. Beilby^{91,92}, Robert W. Lawrence⁶⁵, Robert Clarke⁹³, Rory Collins⁹³, Jemma C Hopewell⁹³, Halit Ongen³², Albert W. Dreisbach⁴², Yali Li⁹⁴, J H. Young⁹⁵, Joshua C. Bis²¹, Mika Kähönen⁹⁶, Jorma Viikari⁹⁷, Linda S. Adair⁹⁸, Nanette R. Lee⁹⁹, Ming-Huei Chen¹⁰⁰, Matthias Olden^{101,102}, Cristian Pattaro³⁰, Judith A. Hoffman Bolton¹⁰³, Anna Köttgen^{104,103}, Sven Bergmann^{105,106}, Vincent Mooser¹⁰⁷, Nish Chaturvedi¹⁰⁸, Timothy M. Frayling¹⁰⁹, Muhammad Islam¹¹⁰, Tazeen H. Jafar¹¹⁰, Jeanette Erdmann¹¹¹, Smita R. Kulkarni¹¹², Stefan R. Bornstein⁷⁶, Jürgen Grässler⁷⁶, Leif Groop^{113,114}, Benjamin F. Voight¹¹⁵, Johannes Kettunen^{116,126}, Philip Howard¹¹⁷, Andrew Taylor⁴³, Simonetta Guarrera⁶⁰, Fulvio Ricceri^{59,60}, Valur Emilsson¹¹⁸, Andrew Plump¹¹⁸, Inês Barroso^{119,120}, Kay-Tee Khaw⁴⁸, Alan B. Weder¹²¹, Steven C. Hunt¹²², Yan V. Sun⁸¹, Richard N. Bergman¹²³, Francis S. Collins¹²⁴, Lori L. Bonnycastle¹²⁴, Laura J. Scott³¹, Heather M. Stringham³¹, Leena Peltonen^{119,125,126,127}, Markus Perola¹²⁵, Erkki Vartiainen¹²⁵, Stefan-Martin Brand^{128,129}, Jan A. Staessen⁷³, Thomas J. Wang^{6,130}, Paul R. Burton^{12,72}, Maria Soler Artigas¹², Yanbin Dong¹³¹, Harold Snieder^{132,131}, Xiaoling Wang¹³¹, Haidong Zhu¹³¹, Kurt K. Lohman¹³³, Megan E. Rudock⁵¹, Susan R Heckbert^{134,135}, Nicholas L Smith^{134,136,135}, Kerri L Wiggins¹³⁷, Ayo Doumatey⁷⁴, Daniel Shriner⁷⁴, Gudrun Veldre^{25,138}, Margus Viigimaa^{139,140}, Sanjay Kinra¹⁴¹, Dorairajan Prabhakaran¹⁴², Vikal Tripathy¹⁴², Carl D. Langefeld⁷⁹, Annika Rosengren¹⁴³, Dag S. Thelle¹⁴⁴, Anna Maria Corsi¹⁴⁵, Andrew Singleton⁸³, Terrence Forrester¹⁴⁶, Gina Hilton¹, Colin A. McKenzie¹⁴⁶, Tunde Salako¹⁴⁷, Naoharu Iwai¹⁴⁸, Yoshikuni Kita¹⁴⁹, Toshio Ogihara¹⁵⁰, Takayoshi Ohkubo^{149,151}, Tomonori Okamura¹⁴⁸, Hirotugu Ueshima¹⁵², Satoshi Umemura¹⁵³, Susana Eyheramendy¹⁵⁴, Thomas Meitinger^{155,156}, H.-Erich Wichmann^{157,158,159}, Yoon Shin Cho⁴⁴, Hyung-Lae Kim⁴⁴, Jong-Young Lee⁴⁴, James Scott¹⁶⁰, Joban S. Sehmi^{160,41}, Weihua Zhang¹⁸, Bo Hedblad³⁹, Peter Nilsson³⁹, George Davey Smith⁶², Andrew Wong⁶⁷, Narisu

Narisu¹²⁴, Alena Stančáková⁵³, Leslie J. Raffel¹⁶¹, Jie Yao¹⁶¹, Sekar Kathiresan^{162,27}, Chris O'Donnell^{163,27,9}, Stephen M. Schwartz¹³⁴, M. Arfan Ikram^{13,15}, W. T. Longstreth Jr.¹⁶⁴, Thomas H. Mosley¹⁶⁵, Sudha Seshadri¹⁶⁶, Nick R.G. Shrine¹², Louise V. Wain¹², Mario A. Morken¹²⁴, Amy J. Swift¹²⁴, Jaana Laitinen¹⁶⁷, Inga Prokopenko^{51,168}, Paavo Zitting¹⁶⁹, Jackie A. Cooper⁶⁹, Steve E. Humphries⁶⁹, John Danesh⁴⁸, Asif Rasheed¹⁷⁰, Anuj Goel³², Anders Hamsten¹⁷¹, Hugh Watkins³², Stephan J.L. Bakker¹⁷², Wiek H. van Gilst⁴⁵, Charles S. Janipalli⁴⁷, K. Radha Mani⁴⁷, Chittaranjan S. Yajnik¹¹², Albert Hofman¹³, Francesco U.S. Mattace-Raso^{13,14}, Ben A. Oostra¹⁷³, Ayse Demirkan¹³, Aaron Isaacs¹³, Fernando Rivadeneira^{13,14}, Edward G Lakatta¹⁷⁴, Marco Orru^{175,176}, Angelo Scuteri¹⁷⁴, Mika Ala-Korpela^{177,178,179}, Antti J Kangas¹⁷⁷, Leo-Pekka Lyytikäinen⁵⁸, Pasi Soininen^{177,178}, Taru Tukiainen^{180,181,177}, Peter Würtz^{177,18,180}, Rick Twee-Hee Ong^{56,57,182}, Marcus Dörr¹⁸³, Heyo K. Kroemer¹⁸⁴, Uwe Völker²⁰, Henry Völzke¹⁸⁵, Pilar Galan¹⁸⁶, Serge Hercberg¹⁸⁶, Mark Lathrop²⁴, Diana Zelenika²⁴, Panos Deloukas¹¹⁹, Massimo Mangino²⁸, Tim D. Spector²⁸, Guangju Zhai²⁸, James F. Meschia¹⁸⁷, Michael A. Nalls⁸³, Pankaj Sharma¹⁸⁸, Janos Terzic¹⁸⁹, M. J. Kranthi Kumar⁴⁷, Matthew Denniff⁷¹, Ewa Zukowska-Szczechowska¹⁹⁰, Lynne E. Wagenknecht⁷⁹, F. Gerald R. Fowkes¹⁹¹, Fadi J. Charchar¹⁹², Peter E.H. Schwarz¹⁹³, Caroline Hayward⁷⁰, Xiuqing Guo¹⁶¹, Charles Rotimi⁷⁴, Michiel L. Bots⁶³, Eva Brand¹⁹⁴, Nilesh J. Samani^{71,72}, Ozren Polasek¹⁹⁵, Philippa J. Talmud⁶⁹, Fredrik Nyberg^{68,196}, Diana Kuh⁶⁷, Maris Laan²⁵, Kristian Hveem⁶⁶, Lyle J. Palmer^{197,198}, Yvonne T. van der Schouw⁶³, Juan P. Casas¹⁹⁹, Karen L. Mohlke⁶¹, Paolo Vineis^{200,60}, Olli Raitakari²⁰¹, Santhi K. Ganesh²⁰², Tien Y. Wong^{203,204}, E Shyong Tai^{205,57,206}, Richard S. Cooper⁵⁴, Markku Laakso⁵³, Dabeeru C. Rao²⁰⁷, Tamara B. Harris²², Richard W. Morris²⁰⁸, Anna F. Dominiczak²⁰⁹, Mika Kivimäki²¹⁰, Michael G. Marmot²¹⁰, Tetsuro Miki⁴⁹, Danish Saleheen^{170,48}, Giriraj R. Chandak⁴⁷, Josef Coresh²¹¹, Gerjan Navis²¹², Veikko Salomaa¹²⁵, Bok-Ghee Han⁴⁴, Xiaofeng Zhu⁹⁴, Jaspal S. Kooner^{160,41}, Olle Melander³⁹, Paul M Ridker^{8,213,9}, Stefania Bandinelli²¹⁴, Ulf B. Gyllenstein³⁷, Alan F. Wright⁷⁰, James F. Wilson³⁴, Luigi Ferrucci³³, Martin Farrall³², Jaakko Tuomilehto^{215,216,217,218}, Peter P. Pramstaller^{30,219}, Roberto Elosua^{29,220}, Nicole Soranzo^{119,28}, Eric J.G. Sijbrands^{13,14}, David Altshuler^{221,115}, Ruth J.F. Loos²³, Alan R. Shuldiner^{26,222}, Christian Gieger¹⁵⁷, Pierre Meneton²²³, Andre G. Uitterlinden^{13,14,15}, Nicholas J. Wareham²³, Vilmundur Gudnason^{10,11}, Jerome I. Rotter¹⁶¹, Rainer Rettig²²⁴, Manuela Uda¹⁷⁵, David P. Strachan⁵⁰, Jacqueline C.M. Witteman^{13,15}, Anna-Liisa Hartikainen²²⁵, Jacques S. Beckmann^{105,226}, Eric Boerwinkle²²⁷, Ramachandran S. Vasan^{6,228}, Michael Boehnke³¹, Martin G. Larson^{6,229}, Marjo-Riitta Järvelin^{18,230,231,232,233}, Bruce M. Psaty^{21,135*}, Gonçalo R Abecasis^{19*}, Aravinda Chakravarti^{1*#}, Paul Elliott^{18,233*}, Cornelia M. van Duijn^{13,234*}, Christopher Newton-Cheh^{27,115*#}, Daniel Levy^{6,16,7*#}, Mark J. Caulfield^{4*#}, Toby Johnson^{4*}

* contributed equally

#to whom correspondence should be addressed: aravinda@jhmi.edu;

m.j.caulfield@qmul.ac.uk; levyd@nhlbi.nih.gov; p.b.munroe@qmul.ac.uk;

cnewtonchekh@partners.org

Affiliations

1. Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
2. Institute of Social and Preventive Medicine (IUMSP), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Bugnon 17, 1005 Lausanne, Switzerland
3. Cardiology, Department of Specialties of Internal Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva 14, Switzerland
4. Clinical Pharmacology and The Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
5. Department of Biostatistics, University of Washington, Seattle, WA, USA
6. Framingham Heart Study, Framingham, MA, USA
7. National Heart Lung, and Blood Institute, Bethesda, MD, USA
8. Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston MA 02215, USA
9. Harvard Medical School, Boston, MA, USA
10. Icelandic Heart Association, Kopavogur, Iceland
11. University of Iceland, Reykjavik, Iceland
12. Department of Health Sciences, University of Leicester, University Rd, Leicester LE1 7RH, UK
13. Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
14. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
15. Netherlands Consortium for Healthy Aging (NCHA), Netherland Genome Initiative (NGI), The Netherlands
16. Center for Population Studies, National Heart Lung, and Blood Institute, Bethesda, MD, USA
17. Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
18. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK
19. Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48103, USA
20. Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
21. Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, WA, USA
22. Laboratory of Epidemiology, Demography, Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA
23. MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge CB2 0QQ, UK
24. Centre National de Génotypage, Commissariat à L'Energie Atomique, Institut de Génomique, Evry, France
25. Institute of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu 51010, Estonia
26. University of Maryland School of Medicine, Baltimore, MD, USA, 21201, USA
27. Center for Human Genetic Research, Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, 02114, USA
28. Department of Twin Research & Genetic Epidemiology, King's College London, UK

29. Cardiovascular Epidemiology and Genetics, Institut Municipal d'Investigacio Medica, Barcelona Biomedical Research Park, 88 Doctor Aiguader, 08003 Barcelona, Spain
30. Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Viale Druso 1, 39100 Bolzano, Italy - Affiliated Institute of the University of Lübeck, Germany
31. Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, 48109, USA
32. Department of Cardiovascular Medicine, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
33. Clinical Research Branch, National Institute on Aging, Baltimore MD 21250, USA
34. Centre for Population Health Sciences, University of Edinburgh, EH89AG, UK
35. Centre for Population Health Sciences and Institute of Genetics and Molecular Medicine, College of Medicine and Vet Medicine, University of Edinburgh, EH8 9AG, UK
36. Croatian Centre for Global Health, University of Split, Croatia
37. Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden
38. Amgen, 1 Kendall Square, Building 100, Cambridge, MA 02139, USA
39. Department of Clinical Sciences, Lund University, Malmö, Sweden
40. Department of Medicine, University of Verona, Italy
41. Ealing Hospital, London, UB1 3HJ, UK
42. Department of Medicine, University of Mississippi Medical Center, USA
43. Genetic Epidemiology Group, Epidemiology and Public Health, UCL, London, WC1E 6BT, UK
44. Center for Genome Science, National Institute of Health, Seoul, Korea
45. Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
46. Departments of Epidemiology and Medicine, Johns Hopkins University, Baltimore MD, USA
47. Centre for Cellular and Molecular Biology (CCMB), Council of Scientific and Industrial Research (CSIR), Uppal Road, Hyderabad 500 007, India
48. Department of Public Health and Primary Care, University of Cambridge, CB1 8RN, UK
49. Department of Basic Medical Research and Education, and Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, 791-0295, Japan
50. Division of Community Health Sciences, St George's University of London, London, SW17 0RE, UK
51. Epidemiology & Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
52. Division of Biostatistics and Department of Genetics, School of Medicine, Washington University in St. Louis, Saint Louis, Missouri 63110, USA
53. Department of Medicine, University of Eastern Finland and Kuopio University Hospital, 70210 Kuopio, Finland
54. Department of Preventive Medicine and Epidemiology, Loyola University Medical School, Maywood, IL, USA
55. Department of Laboratory Medicine & Institute of Human Genetics, University of California San Francisco, 513 Parnassus Ave. San Francisco CA 94143, USA
56. Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, 138672, Singapore
57. Centre for Molecular Epidemiology, Yong Loo Lin School of Medicine, National University of

Singapore, Singapore, 117597, Singapore

58. Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, Tampere, 33521, Finland
59. Department of Genetics, Biology and Biochemistry, University of Torino, Via Santena 19, 10126, Torino, Italy
60. Human Genetics Foundation (HUGE), Via Nizza 52, 10126, Torino, Italy
61. Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599, USA
62. MRC Centre for Causal Analyses in Translational Epidemiology, School of Social & Community Medicine, University of Bristol, Bristol BS8 2BN, UK
63. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Heidelberglaan 100, 3508 GA Utrecht, The Netherlands
64. Complex Genetics Section, Department of Medical Genetics - DBG, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
65. Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Crawley, WA, Australia
66. HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, 7600 Levanger, Norway
67. MRC Unit for Lifelong Health & Ageing, London, WC1B 5JU, UK
68. Occupational and Environmental Medicine, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden
69. Centre for Cardiovascular Genetics, University College London, London WC1E 6JF, UK
70. MRC Human Genetics Unit and Institute of Genetics and Molecular Medicine, Edinburgh, EH2, UK
71. Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK
72. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, LE3 9QP, UK
73. Studies Coordinating Centre, Division of Hypertension and Cardiac Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Campus Sint Rafaël, Kapucijnenvoer 35, Block D, Box 7001, 3000 Leuven, Belgium
74. Center for Research on Genomics and Global Health, National Human Genome Research Institute, Bethesda, MD 20892, USA
75. Columbia University, NY, USA
76. Department of Medicine III, Medical Faculty Carl Gustav Carus at the Technical University of Dresden, 01307 Dresden, Germany
77. Epidemiology and Biostatistics, School of Public Health, Imperial College, London, W2 1PG, UK
78. Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
79. Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA
80. A list of consortium members is supplied in the Supplementary Materials
81. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA
82. Division of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas at Houston Health Science Center, 12 Herman Pressler, Suite 453E, Houston, TX 77030, USA

83. Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA
84. Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, Maryland, USA
85. Washington Hospital Center, Division of Cardiology, Washington DC, USA
86. ALSPAC Laboratory, University of Bristol, Bristol, BS8 2BN, UK
87. Pediatric Epidemiology Center, University of South Florida, Tampa, FL, USA
88. Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK
89. University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK
90. Genetic Epidemiology Group, Department of Epidemiology and Public Health, UCL, London WC1E 6BT, UK
91. Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA, Australia
92. Molecular Genetics, PathWest Laboratory Medicine, Nedlands, WA, Australia
93. Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, OX3 7LF, UK
94. Department of Epidemiology and Biostatistics, Case Western Reserve University, 2103 Cornell Road, Cleveland, OH 44106, USA
95. Department of Medicine, Johns Hopkins University, Baltimore, USA
96. Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, 33521, Finland
97. Department of Medicine, University of Turku and Turku University Hospital, Turku, 20521, Finland
98. Department of Nutrition, University of North Carolina, Chapel Hill, NC, 27599, USA
99. Office of Population Studies Foundation, University of San Carlos, Talamban, Cebu City 6000, Philippines
100. Department of Neurology and Framingham Heart Study, Boston University School of Medicine, Boston, MA, 02118, USA
101. Department of Internal Medicine II, University Medical Center Regensburg, 93053 Regensburg, Germany
102. Department of Epidemiology and Preventive Medicine, University Medical Center Regensburg, 93053 Regensburg, Germany
103. Department of Epidemiology, Johns Hopkins University, Baltimore MD, USA
104. Renal Division, University Hospital Freiburg, Germany
105. Département de Génétique Médicale, Université de Lausanne, 1015 Lausanne, Switzerland
106. Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
107. Division of Genetics, GlaxoSmithKline, Philadelphia, Pennsylvania 19101, USA
108. International Centre for Circulatory Health, National Heart & Lung Institute, Imperial College, London, UK
109. Genetics of Complex Traits, Peninsula Medical School, University of Exeter, UK
110. Department of Community Health Sciences & Department of Medicine, Aga Khan University, Karachi, Pakistan
111. Medizinische Klinik II, Universität zu Lübeck, Lübeck, Germany
112. Diabetes Unit, KEM Hospital and Research Centre, Rasta Peth, Pune-411011, Maharashtra, India
113. Department of Clinical Sciences, Diabetes and Endocrinology Research Unit, University

Hospital, Malmö, Sweden

114. Lund University, Malmö 20502, Sweden

115. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, 02139, USA

116. Department of Chronic Disease Prevention, National Institute for Health and Welfare, FIN-00251 Helsinki, Finland

117. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK

118. Merck Research Laboratory, 126 East Lincoln Avenue, Rahway, NJ 07065, USA

119. Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK

120. University of Cambridge Metabolic Research Labs, Institute of Metabolic Science Addenbrooke's Hospital, CB2 0QQ, Cambridge, UK

121. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

122. Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, UT, USA

123. Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA

124. National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA

125. National Institute for Health and Welfare, 00271 Helsinki, Finland

126. FIMM, Institute for Molecular Medicine, Finland, Biomedicum, P.O. Box 104, 00251 Helsinki, Finland

127. Broad Institute, Cambridge, Massachusetts 02142, USA

128. Leibniz-Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Münster, Münster, Germany

129. Medical Faculty of the Westfalian Wilhelms University Muenster, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany

130. Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA

131. Georgia Prevention Institute, Department of Pediatrics, Medical College of Georgia, Augusta, GA, USA

132. Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

133. Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA

134. Department of Epidemiology, University of Washington, Seattle, WA, 98195, USA

135. Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA

136. Seattle Epidemiologic Research and Information Center, Veterans Health Administration Office of Research & Development, Seattle, WA 98108, USA

137. Department of Medicine, University of Washington, 98195, USA

138. Department of Cardiology, University of Tartu, L. Puusepa 8, 51014 Tartu, Estonia

139. Tallinn University of Technology, Institute of Biomedical Engineering, Ehitajate tee 5, 19086 Tallinn, Estonia

140. Centre of Cardiology, North Estonia Medical Centre, Sütiste tee 19, 13419 Tallinn, Estonia

141. Division of Non-communicable disease Epidemiology, The London School of Hygiene and Tropical Medicine London, Keppel Street, London WC1E 7HT, UK

142. South Asia Network for Chronic Disease, Public Health Foundation of India, C-1/52, SDA, New Delhi 100016, India
143. Department of Emergency and Cardiovascular Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 41685 Gothenburg, Sweden
144. Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, 0317 Oslo, Norway
145. Tuscany Regional Health Agency, Florence, Italy
146. Tropical Medicine Research Institute, University of the West Indies, Mona, Kingston, Jamaica
147. University of Ibadan, Ibadan, Nigeria
148. Department of Genomic Medicine, and Department of Preventive Cardiology, National Cerebral and Cardiovascular Research Center, Suita, 565-8565, Japan
149. Department of Health Science, Shiga University of Medical Science, Otsu, 520-2192, Japan
150. Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita, 565-0871, Japan
151. Tohoku University Graduate School of Pharmaceutical Sciences and Medicine, Sendai, 980-8578, Japan
152. Lifestyle-related Disease Prevention Center, Shiga University of Medical Science, Otsu, 520-2192, Japan
153. Department of Medical Science and Cardioresenal Medicine, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan
154. Department of Statistics, Pontificia Universidad Catolica de Chile, Vicuña Mackenna 4860, Santiago, Chile
155. Institute of Human Genetics, Helmholtz Zentrum Munich, German Research Centre for Environmental Health, 85764 Neuherberg, Germany
156. Institute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
157. Institute of Epidemiology, Helmholtz Zentrum Munich, German Research Centre for Environmental Health, 85764 Neuherberg, Germany
158. Chair of Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, 81377 Munich, Germany
159. Klinikum Grosshadern, 81377 Munich, Germany
160. National Heart and Lung Institute, Imperial College London, London, UK, W12 0HS, UK
161. Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
162. Medical Population Genetics, Broad Institute of Harvard and MIT, 5 Cambridge Center, Cambridge MA 02142, USA
163. National Heart, Lung and Blood Institute and its Framingham Heart Study, 73 Mount Wayte Ave., Suite #2, Framingham, MA 01702, USA
164. Department of Neurology and Medicine, University of Washington, Seattle, USA
165. Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson, MS, USA
166. Department of Neurology, Boston University School of Medicine, USA
167. Finnish Institute of Occupational Health, Finnish Institute of Occupational Health, Aapistie 1, 90220 Oulu, Finland
168. Wellcome Trust Centre for Human Genetics, University of Oxford, UK
169. Lapland Central Hospital, Department of Physiatrics, Box 8041, 96101 Rovaniemi, Finland

170. Center for Non-Communicable Diseases Karachi, Pakistan
171. Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
172. Department of Internal Medicine, University Medical Center Groningen, University of Groningen, The Netherlands
173. Department of Medical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
174. Gerontology Research Center, National Institute on Aging, Baltimore, MD 21224, USA
175. Istituto di Neurogenetica e Neurofarmacologia, Consiglio Nazionale delle Ricerche, Cittadella Universitaria di Monserrato, Monserrato, Cagliari, Italy
176. Unita` Operativa Semplice Cardiologia, Divisione di Medicina, Presidio Ospedaliero Santa Barbara, Iglesias, Italy
177. Computational Medicine Research Group, Institute of Clinical Medicine, University of Oulu and Biocenter Oulu, 90014 University of Oulu, Oulu, Finland
178. NMR Metabonomics Laboratory, Department of Biosciences, University of Eastern Finland, 70211 Kuopio, Finland
179. Department of Internal Medicine and Biocenter Oulu, Clinical Research Center, 90014 University of Oulu, Oulu, Finland
180. Institute for Molecular Medicine Finland FIMM, 00014 University of Helsinki, Helsinki, Finland
181. Department of Biomedical Engineering and Computational Science, School of Science and Technology, Aalto University, 00076 Aalto, Espoo, Finland
182. NUS Graduate School for Integrative Sciences & Engineering (NGS) Centre for Life Sciences (CeLS), Singapore, 117456, Singapore
183. Department of Internal Medicine B, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
184. Institute of Pharmacology, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
185. Institute for Community Medicine, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
186. U557 Institut National de la Santé et de la Recherche Médicale, U1125 Institut National de la Recherche Agronomique, Université Paris 13, Bobigny, France
187. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
188. Imperial College Cerebrovascular Unit (ICCRU), Imperial College, London, W6 8RF, UK
189. Faculty of Medicine, University of Split, Croatia
190. Department of Internal Medicine, Diabetology, and Nephrology, Medical University of Silesia, 41-800, Zabrze, Poland
191. Public Health Sciences section, Division of Community Health Sciences, University of Edinburgh, Medical School, Teviot Place, Edinburgh, EH8 9AG, UK
192. School of Science and Engineering, University of Ballarat, 3353 Ballarat, Australia
193. Prevention and Care of Diabetes, Department of Medicine III, Medical Faculty Carl Gustav Carus at the Technical University of Dresden, 01307 Dresden, Germany
194. University Hospital Münster, Internal Medicine D, Münster, Germany
195. Department of Medical Statistics, Epidemiology and Medical Informatics, Andrija Stampar School of Public Health, University of Zagreb, Croatia
196. AstraZeneca R&D, 431 83 Mölndal, Sweden
197. Genetic Epidemiology & Biostatistics Platform, Ontario Institute for Cancer Research, Toronto

198. Samuel Lunenfeld Institute for Medical Research, University of Toronto, Canada
199. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, UK
200. Department of Epidemiology and Public Health, Imperial College, Norfolk Place London W2 1PG, UK
201. Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku and the Department of Clinical Physiology, Turku University Hospital, Turku, 20521, Finland
202. Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
203. Singapore Eye Research Institute, Singapore, 168751, Singapore
204. Department of Ophthalmology, National University of Singapore, Singapore, 119074, Singapore
205. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore
206. Duke-National University of Singapore Graduate Medical School, Singapore, 169857, Singapore
207. Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, 63110, USA
208. Department of Primary Care & Population Health, UCL, London, UK, NW3 2PF, UK
209. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK
210. Epidemiology Public Health, UCL, London, UK, WC1E 6BT, UK
211. Departments of Epidemiology, Biostatistics, and Medicine, Johns Hopkins University, Baltimore MD, USA
212. Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, The Netherlands
213. Division of Cardiology, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston MA 02215, USA
214. Geriatric Rehabilitation Unit, Azienda Sanitaria Firenze (ASF), Florence, Italy
215. National Institute for Health and Welfare, Diabetes Prevention Unit, 00271 Helsinki, Finland
216. Hjelt Institute, Department of Public Health, University of Helsinki, 00014 Helsinki, Finland
217. South Ostrobothnia Central Hospital, 60220 Seinäjoki, Finland
218. Red RECAVA Grupo RD06/0014/0015, Hospital Universitario La Paz, 28046 Madrid, Spain
219. Department of Neurology, General Central Hospital, 39100 Bolzano, Italy
220. CIBER Epidemiología y Salud Pública, 08003 Barcelona
221. Department of Medicine and Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
222. Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, Baltimore, MD, USA
223. U872 Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Paris, France
224. Institute of Physiology, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
225. Institute of Clinical Medicine/Obstetrics and Gynecology, University of Oulu, Finland
226. Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland

- 227. Human Genetics Center, 1200 Hermann Pressler, Suite E447 Houston, TX 77030, USA
- 228. Division of Epidemiology and Prevention, Boston University School of Medicine, Boston, MA, USA
- 229. Department of Mathematics, Boston University, Boston, MA, USA
- 230. Institute of Health Sciences, University of Oulu, BOX 5000, 90014 University of Oulu, Finland
- 231. Biocenter Oulu, University of Oulu, BOX 5000, 90014 University of Oulu, Finland
- 232. National Institute for Health and Welfare, Box 310, 90101 Oulu, Finland
- 233. MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK
- 234. Centre of Medical Systems Biology (CMSB 1-2), NCI Erasmus Medical Center, Rotterdam, The Netherlands

Acknowledgments

A number of the participating studies and authors are members of the CHARGE and Global BPgen consortia. Many funding mechanisms by NIH/NHLBI, European, and private funding agencies contributed to this work and a full list is provided in Section 21 of the Supplementary Materials.

Author contributions

Full author contributions and roles are listed in the Supplementary Materials Section 19.